Bioventus (NASDAQ:BVS) filed a prospectus related to the offer and sale of $200M mixed securities self. This prospectus is not an offer to sell. Filing
More on Bioventus
Bioventus announces divestiture of its Advanced Rehabilitation business to Accelmed Partners Bioventus reports Q2 results; raises guidance Seeking Alpha's Quant Rating on Bioventus